Skip to main content

Table 1 Demographic data and clinical characteristics among patients

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

  Non- SS SS  
  (n = 98,310) (n = 6554) P-value
Age, years (mean ± SD) 54 ± 14 54 ± 14 1
  < 50 years 34,140 (34.7) 2276 (34.7)  
  ≥ 50 years 64,170 (65.3) 4278 (65.3)  
Gender    1
 Female 86,760 (88.3) 5784 (88.3)  
 Male 11,550 (11.8) 770 (11.8)  
CCI (mean ± SD) 0.4 ± 1.0 0.5 ± 0.9 <0.001
CCI group    
 0 76,836 (78.2) 4541 (69.3)  
  ≥ 1 21,474 (21.8) 2013 (30.7)  
Medications during all follow-up period    
 Immunosuppressants 837(0.9) 1349(20.6) <0.001
  Methotrexate 391(0.4) 563(8.6) <0.001
  Azathioprine 84(0.1) 819(12.5) <0.001
  Cyclophosphamide 425(0.4) 208(3.2) <0.001
 Steroid 38,348(39.0) 4559(69.6) <0.001
Medications during the first year    
 Immunosuppressants 413 (0.4) 955 (14.6) <0.001
  Methotrexate 214 (0.2) 360 (5.5) <0.001
  Azathioprine 41 (0.0) 572 (8.7) <0.001
  Cyclophosphamide 178 (0.2) 150 (2.3) <0.001
 Steroid 19,828 (20.2) 3588 (54.8) <0.001
  1. Abbreviations: SS Sjögren’s Syndrome